SK Biopharmaceuticals Sustainability Profile
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy. With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
DitchCarbon Score
How does SK Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK Biopharmaceuticals's score of 48 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 12,882,000 kg CO2e, comprising 433,000 kg CO2e from Scope 1, 1,046,000 kg CO2e from Scope 2, and 11,882,000 kg CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 and Scope 2 emissions compared to 2022, where total emissions were about 6,547,000 kg CO2e for Scope 3, 425,000 kg CO2e for Scope 1, and 936,000 kg CO2e for Scope 2. The company has not set specific reduction targets or initiatives as part of its climate commitments, and there are no disclosed SBTi (Science Based Targets initiative) reduction targets. However, emissions data is cascaded from its parent company, SK Inc., indicating a corporate commitment to sustainability within the broader SK Group framework. SK Biopharmaceuticals operates with a focus on transparency in emissions reporting, having disclosed emissions across all relevant scopes (1, 2, and 3). The company continues to monitor its carbon footprint as part of its operational strategy, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 328,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 841,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 00,000,000 |
How Carbon Intensive is SK Biopharmaceuticals's Industry?
How Carbon Intensive is SK Biopharmaceuticals's Location?
SK Biopharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SK Biopharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
